Brexpiprazole

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Irritability Associated With Autism Spectrum Disorder

Conditions

Irritability Associated With Autism Spectrum Disorder

Trial Timeline

Jan 23, 2020 → Mar 16, 2023

NCT ID

NCT04258839

About Brexpiprazole

Brexpiprazole is a phase 3 stage product being developed by Lundbeck for Irritability Associated With Autism Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04258839. Target conditions include Irritability Associated With Autism Spectrum Disorder.

What happened to similar drugs?

1 of 4 similar drugs in Irritability Associated With Autism Spectrum Disorder were approved

Approved (1) Terminated (0) Active (3)

✅Aripiprazole + PlaceboBristol Myers SquibbApproved

🔄KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3

🔄Brexpiprazole + PlaceboLundbeckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05504486	Approved	Withdrawn	Aug 29, 2022	Apr 5, 2023	Major Depressive Disorder (MDD)
NCT04830215	Approved	Completed	Apr 1, 2021	May 27, 2022	Major Depressive Disorder
NCT04258839	Phase 3	Completed	Jan 23, 2020	Mar 16, 2023	Irritability Associated With Autism Spectrum Disorder
NCT03548584	Phase 3	Completed	May 16, 2018	Jun 1, 2022	Agitation Associated With Alzheimer's Dementia
NCT03287869	Phase 3	Completed	Oct 24, 2017	Jul 31, 2019	Bipolar I Disorder
NCT03292848	Phase 1	Completed	Oct 10, 2017	May 21, 2018	ADHD
NCT03238326	Phase 3	Completed	Aug 23, 2017	Apr 22, 2025	Schizophrenia
NCT01944969	Phase 3	Terminated	Oct 1, 2013	May 1, 2014	Major Depressive Disorder
NCT01942785	Phase 3	Completed	Oct 1, 2013	—	Major Depressive Disorder
NCT01942733	Phase 3	Completed	Sep 1, 2013	Aug 1, 2014	Sleep Disturbances
NCT01810783	Phase 3	Completed	Jul 1, 2013	Dec 1, 2015	Schizophrenia

Competing Products

7 competing products in Irritability Associated With Autism Spectrum Disorder

See all competitors

Product	Company	Stage	Hype Score
KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo	Bristol Myers Squibb	Phase 3	47
KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo	Bristol Myers Squibb	Phase 3	47
Aripiprazole + Placebo	Bristol Myers Squibb	Approved	43
Brexpiprazole + Placebo	Lundbeck	Phase 3	37
JZP541	Jazz Pharmaceuticals	Phase 2	24
Pimavanserin	Acadia Pharmaceuticals	Phase 2/3	27
Pimavanserin + Placebo	Acadia Pharmaceuticals	Phase 2/3	35